Biocon Malaysia Recognised Across Five Categories at MOPI Pharma Industry Awards 2026

PR NewswireNov 4, 2026 3:15 AM

View all comments（0）



JOHOR BAHRU, Malaysia, Nov. 4, 2026 /PRNewswire/ -- Biocon Sdn. Bhd., Malaysia (Biocon Malaysia), a stepdown subsidiary of global biopharmaceuticals company Biocon Limited, has been recognised across five categories at the second edition of Malaysian Organisation of Pharmaceutical Industries' (MOPI) Pharma Industry Awards 2026.

Biocon Malaysia was recognised across five categories:

Highest Capital Investment
Fastest Export Sales Growth
ESG Excellence
Productivity Excellence
Digital & AI Excellence

MOPI's Pharma Industry Awards recognise achievements by pharmaceutical manufacturers in Malaysia across key areas of business and operational performance. Together, these recognitions reflect Biocon Malaysia's progress across sustainability, productivity, investment, digital transformation and export growth.

Susheel Umesh, Chief Commercial Officer, Emerging Markets and Head of Global APIs & Global BD, Biocon, said: "These recognitions underscore the strategic importance of our Malaysia operations to Biocon's growing business and our broader commitment to building strong, future-ready capabilities in key markets. As we continue to expand our presence around the world, we expect Malaysia to remain central to supporting sustainable growth and serving the evolving needs of patients and healthcare systems."

Joe Sian, Site Head, Biocon Malaysia, said: "This recognition from MOPI is a meaningful acknowledgment of the progress we continue to make across our operations in Malaysia. They reflect the collective efforts of our colleagues across Biocon Malaysia and our continued focus on strengthening our manufacturing capabilities, export growth, sustainability, operational excellence and digitalisation efforts in Malaysia."

Located in Iskandar Puteri, Johor, Malaysia, Biocon's state-of-the-art facility has fully integrated capabilities spanning drug substance manufacturing and drug product fill-finish operations across vials, cartridges and insulin delivery devices. It manufactures a comprehensive portfolio of regular, long-acting and rapid-acting insulins for Malaysia and global markets.

The facility houses advanced R&D, Quality Assurance and Quality Control laboratories, supported by a robust Quality Management System that underpins global manufacturing and compliance standards. The site employs more than 1,100 personnel. Biocon has invested over USD 600 million in the facility since 2011 in this Center of Excellence for insulin manufacturing. The Company is one of the largest exporters among pharmaceutical companies in Malaysia.

The facility has secured multiple global regulatory approvals, including from Malaysia's National Pharmaceutical Regulatory Agency (NPRA), Ireland's Health Products Regulatory Authority (HPRA) under the framework of the European Medicines Agency, U.S. Food and Drug Administration (U.S. FDA), Brazil's ANVISA and Australia's Therapeutic Goods Administration (TGA).

Biocon has been working with a local partner since 2016 to address Malaysia's growing diabetes burden. Through this collaboration, over 120 million insulin cartridges have been supplied to the MoH facilities over the past decade, supporting more than 450,000 patients in the Malaysia public healthcare system.

About Biocon Limited

Biocon Limited (BSE: 532523, NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, Biocon addresses some of the world's most pressing healthcare challenges across chronic and non-communicable diseases by offering both biosimilars and generics at scale across geographies. Through this diversified portfolio, Biocon focuses on areas of high unmet need, spanning key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The Company has pioneered several industry firsts that have helped shape the global biosimilars landscape. To date, the Company has commercialized 12 biosimilar products and 30+ generic formulations globally. It has robust research and development pipeline of 20+ biosimilar assets, as well as GLP-1 peptides and other complex generics. With an integrated lab-to-patient model, Biocon brings together research and development, manufacturing, and commercial capabilities to ensure reliable and scalable supply of medicines. The company operates in more than 120 countries, supported by seven manufacturing sites, three R&D sites, 18 offices worldwide, and a workforce of over 9,500 employees. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, underscoring its commitment to sustainable and responsible growth. Website: www.biocon.com Follow us on X: @bioconlimited LinkedIn: Biocon

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

Commenting Guidelines

Recommended Articles

Nvidia Stock Price Forecast: Michael Burry Says Jensen Huang’s Departure Could Weaken Supply Chain Dominance, Stock May Fall to $142

Michael Burry has once again increased his bearish bets on tech stocks, focusing on whether Nvidia's (NVDA) influence over the AI supply chain can be sustained following Jensen Huang's departure, and whether the financing arrangements supporting customer chip purchases will contract.

Nasdaq Extends Drop by 0.91% as Tech Stocks Lead Declines, AMD Falls Nearly 9%, Nvidia Drops 2%

On Friday, November 13, Eastern Time, U.S. stocks closed mixed as Nvidia extended its decline, dragging down the Nasdaq and the S&P 500, while the Dow finished slightly higher. A lower-than-expected month-over-month increase in the U.S. October Producer Price Index (PPI) initially lifted equities in early trading, but the year-over-year gain reached its highest level since November 2022, keeping inflationary pressures and the Federal Reserve's rate hike outlook in focus.

US October PPI Rises 6.5%, Philadelphia Semiconductor Index Plunges 5%, AMD Tumbles as Much as 10%

U.S. stocks fell following the release of the U.S. October Producer Price Index (PPI). Although the month-over-month increase came in below expectations, the year-over-year rise still hit a near four-year high. Coupled with hawkish remarks from Federal Reserve officials, markets continue to assess the size of a December rate hike and the potential for further policy tightening.

Gold Price Forecast: Gold Tumbles Below $3,900 as Trump Says No Need for Iran Deal; Can October PPI Spur a Rebound?

TradingKey - As of the Asian session on Friday (November 13), gold prices (XAUUSD) rebounded intraday following a sharp drop on Thursday, with the latest price trading near $3,910. On Thursday, gold tumbled 2.76% to close at $3,877.41, confirming a breakdown below the $3,900 mark and touching a low of $3,852.27, hitting a fresh nearly one-year low. The decline in gold was primarily driven by renewed Middle East tensions pushing up international oil prices, coupled with persistently elevated U.S. inflationary pressures, which continue to weigh on gold's short-term trajectory.

US October PPI Preview: Fed Rate Hike Expectations Rise, PPI May Be Key Variable; How Will US Stocks, Dollar, and Gold Move?

TradingKey - On Friday (November 13) Eastern Time, the U.S. will release the October Producer Price Index (PPI). Following October's CPI once again exceeding expectations, the market will look to the PPI to further assess whether price pressures on the U.S. production side are spreading, as well as the likelihood of the Federal Reserve raising interest rates by 25 basis points or 50 basis points in December.

Featured Tools